Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Estimates By $0.05 EPS

Xeris Biopharma (NASDAQ:XERS) announced its quarterly earnings results on Thursday. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.05, Zacks reports. Xeris Biopharma updated its FY 2025 guidance to EPS.

Xeris Biopharma Stock Up 15.4 %

NASDAQ:XERS traded up $0.58 during midday trading on Thursday, reaching $4.35. The stock had a trading volume of 2,675,418 shares, compared to its average volume of 1,658,106. The stock has a market cap of $648.35 million, a P/E ratio of -9.70 and a beta of 2.32. The firm has a fifty day simple moving average of $3.54 and a two-hundred day simple moving average of $3.24. Xeris Biopharma has a 12-month low of $1.69 and a 12-month high of $4.40.

Analyst Ratings Changes

A number of research firms have recently commented on XERS. HC Wainwright lifted their target price on Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research report on Monday, November 11th. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.